Alphagalileo > Item Display
en-GBde-DEes-ESfr-FR

Cell therapy designed to treat inflammatory bowel disease


The research by the UPV/EHU-University of the Basque Country, in collaboration with Harvard University, has yielded highly encouraging results, and studies in animal models have already begun

The UPV/EHU’s NanoBioCel research group has for many years been developing systems enabling cells to be used as drugs. Cell therapy raises hopes for treating those diseases for which there are as yet no effective pharmacological solutions. Biomaterials, a leading journal in the field of materials sciences and medicine, has just published the paper ‘Multifunctional biomimetic hydrogel systems to boost the immunomodulatory potential of mesenchymal stromal cells’, which reports on the results of one of the lines of research of this group at the UPV/EHU’s Faculty of Pharmacy.

The results obtained are very encouraging and the researchers hope to be able to make headway in a multifunctional cell therapy system to treat inflammatory bowel disease. In fact, they have already commenced studies on ulcerative colitis in animal models.

“Perhaps the best known side is the use of stem cells in regenerative therapies,” said Rosa Hernández, professor of the Faculty of Pharmacy and researcher at CIBER-BBN, "since we have all heard for example about the use of chondrocytes in cartilage regeneration or cardiomyocytes to repair a heart following myocardial infarction. However, our research group is working on evaluating the therapeutic action of stem cells by means of their paracrine effects, in other words, mediated by a set of growth factors and cytokines released by the cells.”

In a whole host of disorders with an inflammatory component, such as ulcerative colitis or Crohn’s disease, a possible beneficial effect following delivery of stem cells has been seen. On the basis of this, this group of researchers, led by Dr Rosa Hernández and Dr Manoli Igartua, embarked on a highly ambitious project three years ago to try and develop systems designed to address the problems arising in clinical trials conducted with these stem cells. In fact, even though the potential of stem cells to treat these inflammatory disorders became clear in these trials, problems, such as the rapid elimination of cells from the body, the possible development of tumours or their reduced capability in releasing therapeutic substances were also detected, so new technological solutions had to be sought.

This group of UPV/EHU researchers, whose leading members are Ainhoa Gonzalez-Pujana and Dr Edorta Santos-Vizcaíno, successfully designed and tested a multifunctional system recently in collaboration with Harvard University in Cambridge (USA), specifically with the group led by Dr David J. Mooney. “Besides stem cells, the system incorporates other elements, such as biomaterials and microparticles that release interferon. That way, the activation of the cells can be prolonged so that they constantly release key cytokines and growth factors to treat these disorders; in addition, the persistence of the cells in the body and the biosafety of the therapy can be improved,” said Dr Hernández.

Ainhoa Gonzalez-Pujana, Kyle H. Vining, David K.Y. Zhang, Edorta Santos-Vizcaino, Manoli Igartua, Rosa Maria Hernandez, David J. Mooney

Multifunctional biomimetic hydrogel systems to boost the immunomodulatory potential of mesenchymal stromal cells

Biomaterials. Volume 257, October 2020, 120266

DOI:10.1016/j.biomaterials.2020.120266
Attached files
  • terapia_celularweb.jpg
Regions: North America, United States, Europe, Spain
Keywords: Health, Medical, Science, Life Sciences

Testimonials

We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet
AlphaGalileo is a great source of global research news. I use it regularly.
Robert Lee Hotz, LA Times

We Work Closely With...


  • BBC
  • The Times
  • National Geographic
  • The University of Edinburgh
  • University of Cambridge
Copyright 2021 by DNN Corp Terms Of Use Privacy Statement